Is Vertex CEO Jeff Leiden paid too much?; Pulmotect gets $3M grant to fuel clinical study;

@FierceBiotech: UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep. Story | Follow @FierceBiotech

@JohnCFierce: CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal. Article | Follow @JohnCFierce

> Corporate governance adviser Institutional Shareholder Services (ISS) believes Vertex ($VRTX) chief Jeff Leiden is overpaid. ISS is urging shareholders to censure the executive pay in a non-binding vote of disapproval June 4, reports Bloomberg. Leiden's pay packet last year was worth $45.8 million. Story

> Houston-based Pulmotect has won a $3 million grant from the NIH to help advance its immunotherapy in the clinic. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: SI-Bone raises $21M, brings on new CFO to grow iFuse implant sales. Article | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. More from FierceDiagnostics | Follow @EmilyWFierce

> CareFusion's Avea ventilator recalled as potentially deadly, FDA says it may cease functioning. Article

> Scientists push back against cancer hereditary genetic tests in NEJM paper. More

> Varian, Flatiron Health to collaborate on oncology electronic health records. Report

Pharma News

@FiercePharma: Regeneus gets green light to move personalized cancer vaccine into PhI. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. FiercePharmaMarketing article | Follow @CarlyHFierce

> Express Scripts pushes pay-for-performance to cut cancer drug prices. Report

> Top Medicare prescribers get top payments from drugmakers: Modern Healthcare. More

> Vertex CEO's $45.8M paycheck spurs call for revolt. Article

Pharma Marketing News

> My bathtub or yours? How a panned Cialis ad became promotional gold. More

> Revving up for price war with Amgen, Sanofi plots low-cost starter dose of PCSK9 med. Story

> Do doc payments push prescriptions? Study of Medicare scripts suggests it's so. Item

> AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. Article

> Can AZ salvage brodalumab against next-gen psoriasis field? More

Biotech Research News

> Dana-Farber researchers tout a new class of cancer-fighting 'degronimids.' More

> Pitt team unveils two new classes of RNAs for cancer drug R&D. Report

> The White House draws the line against CRISPR/Cas9-designed embryos. Story

> Thunder god vine compound may have potent anti-obesity characteristics. More

> Winship research team flags potential of a new lung cancer therapy. Article

Diagnostics News

> MBio receives $6.3M in support of its portable, optical diagnostic. Story

> Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. Item

> Quest Diagnostics shares hit record high amid takeover rumors. Report

> Roche gets FDA green light for quick C. difficile test. Article

> Sequenom stares down suit from Indian genomics firm. More

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.